

# EACR-Boehringer Ingelheim Conference: Drugging and Regulating the MAP Kinase Pathway Programme

*Virtual Event, Worldwide*

**11 - 12 February 2025**



## Scientific Programme

### Tuesday 11th February 2025

**Listed times are in Central European Time (CET)**

13:00 **WELCOME TO DAY ONE**

Chair: Marco Hofmann

13:10 **OPENING KEYNOTE LECTURE**

**Piro Lito**

Memorial Sloan Kettering Cancer Center, USA

'A 'new' old approach to inactivate RAS'

Q&A 13:40-13:55

13:55 **Miriam Molina Arcas**

Francis Crick Institute, UK

'Rational approaches to combine KRAS inhibitors and immunotherapies in lung cancer'

Q&A 14:15-14:25

14:25 **Saptaparna Mukherjee**

Francis Crick Institute, UK

Proffered Paper 1: 'MYC and KRASG12C Cooperation Drives Immune-Evasive Tumour Progression in Lung Adenocarcinoma'

Q&A 14:35-14:40

14:40 **REFRESHMENT BREAK**

Chair: Anna Obenauf

15:00 **Sandra Misale**

John Hopkins University, USA

'Concurrent SOS1 and MEK suppression inhibits signaling and growth of NF1-null melanoma'

Q&A 15:20-15:30

15:30 **Robert Kortum**

Uniformed Services University, USA

Proffered Paper 2: 'SOS1 inhibition enhances the efficacy of and delays resistance to oncogene-targeted therapies in lung adenocarcinoma'

Q&A 15:40-15:45

15:45 **Mallika Singh**

Revolution Medicines, USA

'Targeting the Oncogenic State of RAS with Tri-Complex Inhibitors'

Q&A 16:05-16:15

- 16:15 POSTER SPOTLIGHTS  
16:25 TRANSITION BREAK  
16:35 VIRTUAL POSTER SESSION ONE  
Scheduled to end at 17:35 CET

## Wednesday 12th February 2025

**Listed times are in Central European Time (CET)**

- 12:30 VIRTUAL POSTER SESSION TWO  
Scheduled to end at 13:30 CET
- 14:00 WELCOME TO DAY TWO  
Chair: Chiara Ambrogio
- 14:05 **Marco Hofmann**  
Boehringer Ingelheim, Austria  
'Targeting the RAS Signaling Pathway: Inhibitors and Mechanisms of Resistance'  
Q&A 14:25-14:35
- 14:35 **Alberto Bardelli**  
University of Torino, Italy  
'Adaptive cancer mutability in response to targeted therapies'  
Q&A 14:55-15:05
- 15:05 **Christian Umkehrer**  
Boehringer Ingelheim, Austria  
Proffered Paper 3: 'Dissecting the clonal evolution of resistance to KRAS inhibitors through genetic barcoding and scRNAseq'  
Q&A 15:15-15:20
- 15:20 REFRESHMENT BREAK  
Chair: René Bernards
- 15:40 **Marina Pasca di Magliano**  
University of Michigan Medicine School, USA  
'Oncogenic KRAS mediated regulation of the pancreatic cancer microenvironment'  
Q&A 16:00-16:10
- 16:10 **Gonzalo Aizpurua**  
Spanish National Cancer Research Centre, Spain  
Proffered Paper 4: 'Identifying RAF1 degraders as a therapeutic approach in KRAS-driven lung tumors'  
Q&A 16:20-16:25
- 16:25 CLOSING KEYNOTE LECTURE  
**Colin Lindsay**  
Manchester Cancer Research Centre, UK  
'Bedside to bench to bedside again: leveraging KRAS precision medicine for optimum clinical benefit'  
Q&A 16:55-17:10

17:10 DISCUSSION SESSION

**René Bernards, Anna Obenauf, Marco Hofmann & Chiara Ambrogio**

'New challenges for old therapeutic targets: What's next?'

17:50 SUMMARY AND CLOSE